News in Pediatric Gastroenterology Pharmacology
New direct acting antivirals
Daniele Serranti1Giuseppe Indolfi12
1Epatologia Pediatrica, Azienda Ospedaliero-Universitaria Meyer 2Dipartimento NEUROFARBA, Università degli Studi di Firenze
Direct acting antivirals active against hepatitis C virus actby inhibiting the crucial steps of the viral lifecycle. Theefficacy of these drugs has been demonstrated to be high(>90%) in adults, adolescents and children with chronichepatitis C. Three different combinations of direct actingantivirals have been approved for use in adolescents (≥12years old): sofosbuvir/ledipasvir, sofosbuvir plus ribavirinand glecaprevir/pibrentasvir. The aim of the present articleis to provide a comprehensive description of the currentknowledge on the use of direct acting antivirals in childrenand adolescents.